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Summary 
Informed consent is an ethical and legal requirement for research involving 
human participants. However, there have been few studies that have 
evaluated the process, particularly in an African setting. In addition. 
standardized methods for assessing the quality of informed consent are not 
available in the literature. 
Objective 
The aim of the study was to evaluate the quality of consent in a large 
tuberculosis vaccine immunology study and to identify factors associated with 
the quality of consent. 
Setting 
Participants in an immunology case control study designed to Identify 
correlates of immune protection against TB. This study was nested within a 
randomized clinical trial evaluating BCG vaccine efficacy amongst infants 
born in the Worcester area. 
Methods 
Caregivers of children participating in the immunology study were enrolled 
and interviewed by research nurses. A questionnaire dealing with the key 
requirements of informed process and content (i.e. voluntary participation, 
confidentiality, the main risks and benefits of the immunology study and 
understanding of the material) were completed by participants and the recall 
and understanding of consent items were measured. 
Results & Conclusion 
The majority of participants obtained high scores (> 75%) for both the recall 
and understanding sections. The median score for recall was 66.7% (lOR = 
55.6%-77 8%) and for understanding 75% (IOR=50%-87.5%). Most (79 2%) 
were aware of the risks, but only 36.7% could recall that ther(~ were no direct 
personal benefits. A total of 65.1 % knew that participation was voluntary. 
Education level of the participant and experience of research staff were 
predictive factors for good quality consent. 
Conclusion 
To the knowledge of the author, this is one of a very few studies of its kind in 
South Africa. The quality of informed consent for the immunology study cun 
be considered as acceptable, in the context of public health research in a 
developing country. Although participants could recall most of the 
information of the consent document, there was some uncertainty in their 
perception of benefits. The study could also be useful in providing <3 method 
for informed consent assessments in future studies. 
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Enrollment of pregnant women at antenatal clinics in the northeastern part of 
the Boland region of the Western Cape Province of South Africa commenced 
in March 2001. Worcester, the biggest town of the study area 1, lies 100 km 
northeast of Cape Town, the capital city of the province. 
Figure 1: Map of the Western Cape Province showing the study area (in 
box), the Breede River and the major national routes diverging from 
Cape Town to the interior. 
• 
Nort hern Gape 
Western (ape 
I The study area is situated in the valley of the Breede River, which forms the backbone of its 
predominantly agriculture based economic activities. The data collected during the census 
conducted by Statistics SA in 200 I show that the region had a steady increase in population over 
the previous five years. Tbe region is characterized by a median household income of under R20 
000 per aunum, an unemployment rate of 20%, with less than 10% of adults having finished school. 
The Hex River Valley, flanking a tributary of the Srcede River, houses one of llle richest wine 
producing districts of the country. Here, farmers produce export quality wine that can be sold for 
well over US$100 per case. Yet, farm workers earn as little as RI80 (US$22-30) per week. This is 
frequently the only income available to support up to twelve household members, including young 
children. 
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The health workers possess a 
to counsell 
ic health facilities. 
and are trained 
surveillance :1t 
of individuals who had been in contact with an infectious 
tuberculosis when I A 
level of to be indicative of TB infection. 
I Hereafter referred to as parents. 
5 The research nurses are Professional Nurses who have at least a 3 year at a 
color a 4 year at a 
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contact with adults with aClive TB should also be 
outcomes in trial 
in 
A convenience sa Ie 
I on 
vaccine reactions 
of TB and 
to identify 
13 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
in 
com 
T s were: 
a. 
c. 
d. 
y. 
14 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
immune 
a 
skin 
re 
com re 
on severe 
me 
is 
15 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
r"""LUY consent 
(NIH) 
,a 
16 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
1 ), 
In 1994, the African National came into power du the first democratic 
electIons in South Africa, after decades of governance called A 
Under the of Nelson Mandela, who was for 27 years th 
rtheid occurred in almost all of These 
of the lives of all South Africans were 
disenfranchised black 
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practices, but of those that did, 81 % quoted consent ratestl of 100%. This 
high consent rate could imply that voluntariness was not present In the 
procedures, particularly in large trials and those that involved children. The 
authors argue that journals should require reporting on consent rates in order 
to raise awareness of inadequate consent practices. 
The call for consent-sensitive publication IS supported and emphasized by 
observers who realise that IRBs in developing countries are not always 
constituted to oversee proper review of informed consent practices. 
According to Squire et a/. (1997), ethical review of a South African study 
about the effect of H IV on the clinical outcome of Intensive care patients was 
done by a subcommittee of a postgraduate committee with "questionable 
judgement" This particular IRB was clearly not properly constituted. This 
poses a dilemma for research institutions from industrialized countries as 
their IRBs are considered to be adequately representative of the research 
community. When collaborating in projects in developing countries, however, 
researchers may be faced With a situation where independent review 
processes do not exi st or are weak 
International sponsors of research carried out in d veloping countries may 
also pressurize the I RBs In these countries to approve studies that have 
already been approved by IRBs in the sponsoring country (London, 2002). It 
can be hypothesized that the strict requirements for informed consent are 
mainly to protect the researchers: and not necessarily to protect the 
participant. In order to allay this and other concerns (for instance, that IRBs 
are more alert to procedural correctness than ethical reasoning, and that 
power and money exert undue influence in these IRBs), London (2002) 
proposed ways to improve the regulation of ethics practices in developing 
countries. These measures included proper ethical training to IRB members, 
lay representation and appropriate empowerment of such members in IRBs, 
transparency of IRB activities and decisions, and independent monitoring of 
research activities. 
Some of these measures are endorsed by other leading bioethicists (Benatar, 
2002), who share opinions that ethics IS a dimension of quality that must be 
subject to evaluation. In a commentary about research ethics, Benatar et a/ 
(2001) have lauded efforts to evaluate clinical ethics progress, but 
considered these efforts inadequate to address the problems that perpetuate 
ethics violations in research in developing countries. Weaknesses in 
academic regulatory processes need to be identified and corrected Double 
standards in ethics requirements when dealing with developing country 
research projects need to be eradicated. 
8 Referred to here as the number of selected individuah from whom consent had aCLually been 
obtained. suggesting refusal rates of zero. 
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In gen re is a to varying methodolog and 
I of consent assessments. The literature I e IS sparse, 
Indicating a reluctance to do scientific research on the topic or to publish 
research flndi . More be to explore practices 
and outcomes of informed consent particularly in literacy communities 
and in developing need for to eva 
the quality of informed consent is therefore critical. 
ssment consent quality in med research may produce 
results that reflect poorly on I s, whose role is to protect research 
partici unethical studies. Low ility 
(quality findings in I ustrialised 
I procedures perceptions In addition, poor quality in 
developing countries perhaps raise more Intense questions about human 
rights, equity and However difficult these questions are, it is still 
necessary to invite critical discussion. Scientific I Id ICS 
topics as i I of done by 
requiring reporting on consent in more "ethi 
papers in mainstream scientifiC journals, publishing "ethiCS" debates 
periodically. In this a Increase in rial will generated In 
an area of mefui dearth. 
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A small number of selected clinics had no participants because the 
Immunology Study phlebotomy for those clinics had been postpolled or 
cancelled. Two other clinics which were part of the sample were postponed 
owing to staffing problems on those days, but the clinics were Included in the 
study at the end of the enrollment period. 
On the day of the Consent Study, the study coordinator, a professional nurse, 
would arrive at the clinic where mothers were having consent taken fOI 
enrollment into the Immunology Study using the Immunology Study Consent 
form (Appendix B). The research nurse .in charge of the phlebotomy would 
refer mothers to the Consent Study nurse. Mothers would be told about the 
purpose of the Consent study and asked to participate [see Appendix C: 
Standard operating procedure: Consent Study enrollment and consent and 
Appendices G, H & I: Consent study consent form (in three languages)]. 
Those who agreed would be taken to a private area and given a Consent 
Study questionnaire (Appendices D, E & F) in the appropriate language. The 
Consent Nurse would then explain to the mother how to complete the 
questionnaire, and then remain available for questions and assistance. 
Measurement and data collection 
The quality of informed consent was determined by using two measurements: 
(1) recall of consent document information and (2) understanding of the 
underlYing principles of informed consent. A questionnaire (Appendix C), 
specifically designed for this study, was used and contained the following' 
a) A demographics section for name, study number, date of birth, address, 
level of education, language, contact number and date; 
b) Nine multiple choice questions 10 to test whether the mother: 
I. was aware that the baby was required to participate in a 
research study, and that the visit was not for routine 
primary health care; 
II. knew the purpose of the research; 
III. knew what research procedures were involved; 
IV. knew the duration of the study; 
v. knew what the main risks were; 
VI. knew what the main benefits were; 
VII. was aware that participation was voluntary; 
VIII. was aware that information would be kept confidential; and 
ix. knew what would happen with the infant's stored blood. 
JU Hereafter referred to as "Recall" questions as they test how well participants could rl.:cal1 consent 
document contents (see Table 1a below). 
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Chapter 3: Methods 
Study design 
A cross-sectional study was conducted in the same cohort as the BCG Study 
and the Immunology Study described in Chapter 1. 
Population and sampling 
All participants visiting the clinics for the Immunology Studl phlebotomy 
were eligible for the Consent Study (see Figure 2: Schema of recruitment), 
and participating clinics were visited according to a two-monthly rotating 
schedule (Appendix J) which ranged from once weekly visits (biggest facility) 
to once every two months (smallest facility) . Systematic random sampling of 
clinics was used in order to reduce the chance of selection bias. In order to 
ensure similar numbers of Afrikaans and Xhosa speaking participants, all 
clinics where the language of business is predominantly Xhosa and every 
fourth scheduled clinic where the language of business is predominantly 
Afrikaans were selected. 
Figure 2: Schema of recruitment for the Consent Study 
Pregnant women enrolled at ante-natal clinics 
Int.-adenllal or Pel"cutaneous Japanese 
BCG giHn to I)al"ticipating nen))ol"ns 
(n-J!2 {lOO) in IUatenIit~· units 
"The BCG STUDY" L-________ ~ .-________ __ 
Blood collected fI"onI chihh"en at 
111 neeks of age at I)ublic health 
facilities fIll" immunological tests 
(n-6 (00) 
"The IMMUNOLOGY STUDY" 
Intradel"mal Danish BCG ginn 
to nOn-l)a."ticipating, withd ."awn 
& excluded nenbOI"ns at 
matemity units 
"STANDARD OF CARE" 
Modi r of childrea a k d to 
I)artlcip.t ia tb Quality 0' 
Coa Dt tudy (D ... 192) 
T T D .. 
9 lmllllll1Olog' SllId, P<lrtlcipanl s \\ere ilJI BeG Slud, PiHlicipanls 
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Table Ia: Recall questions of questionnaire 
A. Select the ONE option that best completes the statement legarding the study you were 
asked 10 consent to earlier today (Corrcct answer underlined - tor illustration only. For 
study all options will appear identical in prin!.) 
I. r have been asked to attend the cl inic today so I hat : 
1. My baby can receive expert treatment. 
2. Mv baby can participate in a research study 
3. My baby can receive routine health care 
2. The purpose of thc research study is to : 
I. Test for protection against tuberculosis in mv baby's blood. 
2. Test for tuberculosis in my baby 's blood 
3 . Test for HIV in my baby's blood 
3. Research staff wants to enroll my baby into the research study so that: 
I. They can test my baby for TB or HIV 
2. They can collect blood (rom my baby 
3. They can inject my baby with BCG 
4. The total amount of lime my baby will be expected to participall: in the study is : 
J. 2 to 3 years 
2. 8 to 14 weeks 
3. 1 dol' 
5. The most common risk involved when blood had been collected from my baby is : 
1. My baby can become infected with TB or II/V 
2. My babv mal' suffer verI' slight scarring and. some oozing 
3. My baby can loose too much blood 
6. The benefits available to me and my baby for participating in the study are: 
1. There are no immediate benefits 
2. My baby will be protected against TR 
3. My baby and 1 will get beller treatment at clillics 
7. If I didn't want to participate in this study, I could withdraw and 
1. My baby and I would be denied access to health servi"es at this clinic 
2. My baby and I will be treated differently by research and dlllic sta)! 
3. My baby and I would suffer no loss at all 
8. My baby 's personal details will never be linked with his 1 her blood because 
1. Numbers with barcodes will be used to keep bloods anonymous 
2. Highly trained research staff will keep information seer;::t 
3. Clinic staff will be sure not to give information to the rnearch sta)f 
Q. The blood of my baby that will be frozen and stored wil.l be used 
1. For all kinds of research in other countries 
2. For HIV testing 
3. For other tests concerning protection against TB 
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c) Five differently phrased questions (Table Ib) to cross-check some 
answers in (b); 
Table Ib: Cross-check questions of questionnaire 
Yeo; No Don"t knoll 
10. Tile procedllres done on III' b<lb\ ill thi,; stud) me 
<I. S<lfe <l1lc! pr<lctically 11MIlIless n 0 0 
b. D<lllgerotls ilild bilrmflli. 0 [J 0 
1U. M, bilbY's blood is going to be used to 
<I. help deHlop <l blood test for TH .. 0 0 [] 
b. determine "helher 111) b<lb, Ilil~ TB. 0 0 0 
l2 M\ bilb,"s Hilll\(; is \\'("ilten Oil <III the blood tubes ... 0 0 ~ 
d) Eight "yes/no" questions 11 that tested how participants understood the 
consent concepts Table Ic; 
Table Ie: Understanding questions of questionnaire 
"-- _ .. _-----_. 
Yes No Do Il "t KllO\\ 
I ~ I <lgreed to emoll III' child in this stucly bec<luse 
<I. t-.h cllild might get bettc:r trentlilent .. rl 0 0 
b I \I <lilt doctors 10 belp leMn more <lbout TB .. 0 0 [1 
l~. r",c decidc:d to enroll 111\ bab," in the stuc" 
<l e\ en tbough my bilby \I ill recei\'e no e~dril trciltlllcllt 0 0 0 
b. becallSe 1 Knell r \\ould reccin: il loiletries haillper 0 0 0 
15. H Ill\ bilb, gets [] bfllise frolll the blood test. I ShOltld 
;1. Contilct the police U 0 LJ 
b. Speilk to the IIlJrse llt Ihe clllliC. II 0 0 
c Go to the doctor ilt his pri'<ltc SllJgef\ .. 0 II 0 
16. I lIas enrolled in the study ill 111\ hOllle langl1Clgc .. 0 1I 0 
j ., If I \\(\S gi\ell the choice to partlcip<lte again I \\ollid. 0 n IJ 
f) One question that dealt with whether consent was obtained in the home 
language; 
e) Five questions (Table Id) about health rights as defined in the South 
African Constitution 12; 
II Hereafter referred to as "Understanding" questions Table lc. 
12 The Constitution contains a Bill of Rights \\-hich indudes: 
the right to have access to health care services: 
the right to be free from bodily hann; and 
the right to freedom of Jssociation, r.::ligion, belief. opinion <lnd political choices 
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Table Id: Health rights questions of questionnaire 
Yes No Don't know 
18. WIILCIl of tile following rigllts are protected ill the 
SOllth African constitution') 
(,I) access to health care, 
(b) conceallllent of pri,·ate informatioll .. 
I c) fre~dolll from bodil~ lIartH .. 
(eI) fr~e Ile(llth c(lre to ,111 .. 
. . . .. . . . . . . . . 
(t) freedom of choice ......... 
g) A question inviting comments from participants; and 
D D 0 
0 0 0 
LJ 0 0 
0 0 0 
0 0 0 
h) Two questions about logistics that the study facilitator would answer to 
aid in assessing interview quality, 
The participant completed item (a) to (g), and the research nurse 
completed item (h). The questionnaire was available in three languages, 
English, Afrikaans and Xhosa (Appendices D to F). 
Information collected from the questionnaires included a number of 
variables considered to be influential in the quality of informed consent. 
Table lIa contains details of these "predictor" variables and Table lib 
some of the "outcome" variables, generated from the data. 
Table lIa: List of key predictor variables 
Predictor variables Comments 
Age Calculated from participant date of birth 
Education Given as highest standard completed at school. 
Standard 10 is equal to Grade 12 (equivalent to 
12 years' schooling). 
Socio-economic status Given as access or no access to a telephone, 
(proxy) whether landline or mobile. 
Language Afrikaans or Xhosa 
Research experience of Given as greater than or less than 2 years of 
nurses obtaining consent work experience in the research field 
32 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Table lib: List of key outcome variables 
Outcome variables Comments 
Specific recall scores Number or percentage of participants giving 
correct answers to specific recall questions 
Participant recall score Number or percentage of correctly answered 
recall questions for each participant 
Participant Number or percentage of correct13 answers to 
understanding score understanding questions for each participant 
Health rights questions Number or percentage of participants giving 
correct answers to specific health rights 
questions. 
Participant uncertainty Number or percentage of "Don't know" answers to 
score yes I no questions for each participant 
Pilot study results 
For this study, the new questionnaire was piloted in two ways: 
1. Six participants of the Immunology Study were approached to answer 
the questions. These were the first two recruitments from each of 
three clinics from the phlebotomy schedule. The purpose of this part of 
the pilot study was to determine the time taken to complete the 
questionnaire and the amount of assistance required to complete the 
questionnaire It took volunteers approximately 20 minutes to 
complete the questionnaire, and most volunteers required minimal 
assistance (Table lila). 
Table lila: Pilot study - time taken & assistance required 
Participant Language Time taken Assistance required 
1 Afrikaans 18 minutes Minimal 
2 Afrikaans 12 minutes Minimal 
3 Afrikaans 16 minutes Minimal 
4 Afrikaans 23 minutes Moderate 
5 Xhosa 17 minutes Moderate 
6 Xhosa 25 minutes Minimal 
13 Referred to here as the expected or preferred answers that best illustrate understanding and the 
correct interpretation of items in the jnformed consent document. 
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2, Four members of the reseCirch staff, two research nurses and two 
nurse assistants were asked to answer the questions, None of the 
volunteers thought that the questions were too difficult, and all thought 
that the language used was generally understandable (Table IIlb), 
Table /II(b): Pilot study - Difficulty of questions and language 
Staff member Language Questions Understanding 
1 Afrikaans Easy Good 
2 Afrikaans Some difficult Good 
3 Xhosa Some difficult Slightly difficult 
4 Xhosa Easy Good 
The following additional measures were taken to enhance validity and 
rcpeatabi I ity: 
The questionnaire was translated from English into the two main 
regional languages (Afrikaans and Xhosa), and the translations 
verified by back-translation and piloting; 
All participants were interviewed in their home language; 
Written permission and consent for the Consent Study were 
obtained by a specially trained research nurse within an hour of 
enrollment Into the Immunology Study; 
Appropriately trained research staff conducted the Consent 
Study interviews, and 
A separate research worker monitored the Consent Study 
procedure, including questionnaire checking and scoring, 
All interviews were conducted in the following manner' 
The research nurse enrolled the participant into the Consent 
Study, obtaining informed consent; 
The research nurse handed the participant a questionnaire and 
explained how to complete it, 
The participants completed the questionnaire by themselves, 
without influence from others; 
The research nurse assisted with the explanation of the 
questions, but not with interpretation of the answers; 
The research nurse selected the appropriate answers for the two 
logistics questions; 
The research nurse did not lead answers through prompting; and 
The research nurse reviewed the completed questionnaire for 
obvious omissions and errors in the demographics section, 
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In the absence of norms for acceptable quality of informed consent, the 
scores for the recall section were grouped in the following manner: 
• 75% and more correct, was assigned the "High acceptability" 
classification, 
• 50 - 75% was assigned "Above average acceptability", 
• 25% - 50% was assigned "Below average acceptability", and 
• less than 25% was assigned "Low acceptability". 
The same claSSification was used for the understanding section. 
Ethical considerations 
The Research Ethics Committee of the University of Cape Town Health 
Sciences faculty approved the Consent Study. 
After mothers had been enrolled into the Immunology Study, they were 
referred to the nurse of the Consent Study who was waiting in a separate 
room. An informed consent process was conducted. Participants received a 
simple letter explaining the study and requesting their participation. The 
research nurse explained the Consent Study to the participants, using the 
consent form as a template. If the participants agreed to participate, they 
were asked to sign the consent form. The research nurse also signed. The 
participants were given a signed and dated copy of the consent form to keep. 
An amount of R50, considered to be adequate to reimburse additional 
transport and refreshment costs, were given to the mother at the end of the 
interview. (The Medicines Control Council has previously suggested that 
R 150 be paid per participant in any research protocol approved in South 
Africa from that year onwards, however, this was applicable to clinical trials 
only) 
Research staff also discussed wrong answers in the recall section with 
participants, thereby correcting misconceptions they may have Names and 
addresses were recorded, but only for bookkeeping purposes. 
No personal details were directly linked to any data reporting. 
No apparent harm or injury was anticipated from their participation in the 
Consent Study. 
No benefit was available to participants oHler than the R50 paid for their 
time. 
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Chapter 4: Results 
Response rates 
From 23 March to 28 June 2004, the phlebotomy team visited the twenty-two 
primary health care facilities (clinics) in the study area. One hundred-and-six 
(106) clinic visits were made and 481 participants were enrolled into the 
Immunology Study. Of the 32 visits which were selected for the Consent 
Study, two visits were cancelled, and 202 Immunology Study participants 
were referred to the Consent Study staff. A total of 192 mothers completed 
the questionnaires for the Consent Study, resulting in a response rate of 
95.0% . The non-responders were made up as follows: three left the clinic 
before the Consent Study team had started enrollments, four could not be 
enrolled because of an accidental language mismatch and a further three 
used a spoilt version of the questionnaire . 
Figure 3: Schema to show how participants were selected for the 
Consent Study and relationship with parent studies 
Number of yisits scheduled for the 
Immunology Study: 106 
Immunology Study participan ts 
(As per phlebotomy schedule) 481 
Number of ,isits selected for the 
Consent Study : 32 
(Systematic sampling of ,isits) 
'I 
Chilies callcelled . 2 I 
J 
Number of Consent Study "isits: 30 
I 
Completed questionnaires 
196 (95% ) 
Demographic information 
The study sample was selected out of a total of 481 caregivers of infants 
participating in the Immunology Study over a four-month period . Using the 
phlebotomy schedule of the Immunology Study, the study team visited clinics 
throughout the study area in Worcester, Ceres, Robertson and surrounding 
towns . From Figure 4 it can be seen that Worcester constituted the largest 
source area (48.4%) . Of the 192 participants, 56.8% were consented in 
Afrikaans and 43.2% in Xhosa . More than 95% of participants of the Consent 
Study were enrolled into the Immunology Study in their home language. 
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Figure 4. Distribution of participants by area and language (n=192) 
600% 0 I 50.0% I 40.0% 
30.0% 
20.0% 
10.0% 
0.0% -
Worcester Ceres Robertson 
o Xhosa 14.6% 18.2% 9.4% 
o Afrikaans 33.9% 8.9% 15.1% 
'- '-
Areas 
Between 1 and 15 participants attended the clinics on the study days. As 
Table V indicates, demographic factors of the Consent Study and the BCG 15 
Study have comparable summary statistics. (The Immunology Study is 
nested within the BCG). The BCG Study figures come from data collected 
from the first two years' enrolments. It can be seen that the number of 
participants per clinic (a reflection of how busy the clinics were) for the 
Consent Study was similar to that of the Immunology Study participants. 
Table V. Comparison of demographics between the Consent Study and 
BCG Study 
Aspect Consent Study BCG Study 
(n=192) (n=6140) 
Language (%): Afrikaans 56.8 59.7 
Xhosa 43.2 40.3 
Participant age (years): median (range) 26 (16-44) 26 (14-45) 
Area (%): Ceres 27.1 25.1 
Robertson 24.5 24.1 
Worcester 48.5 50.8 
Participants per clinic: median (range)* 8 (1-15) 7 (1-16) 
• Note that the clinic figures given are for the Consent Study and the Immunology Study. 
15 Data of BeG Study enrolments are used because of availability of appropriate daLa. 
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All participants were women, aged between 16 and 44 years with a median 
age of 26 years (Figure 5). 
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Figure 5. Age distribution of participants (n=192) 
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A total of 171 (89.1 %) of participants had achieved the minimum 
recommended educational level for the Immunology Study (standard 5), and 
65 (33.9%) had completed Standard 10 (or Grade 12), which is equivalent to 
12 years' schooling. The education level distribution is illustrated graphically 
in Figure 6. 
Figure 6. Distribution of educational level of participants (n=192) 
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Table Vila: Results of quality of informed consent assessment: 
Recall section 16 
1. I haH been asl.:ed to attend the clinic today so that (,..=n=--=-=1'-"9-=2'-')-=-: ______ _ 
- , ,\11- hahl' c(//~j~arlicil:!..(/Ie ill a research Sllll~l' 
~. baby can recei'e ex eft treatment. 
----~ 
16~ (85~%) 
1~ ( 7.:>%) I M~ bab~ can recei,'e fo'utine he<llth care ---;--1~ ( 7:>%) 
2. The lUI· lOse of the I·esearch stud, is to (n=191): 
Test/i)r rorl'criOIl 17(!aiIlSI luberculosis ill /Ill' hahy's hlood. 
Test for tuberculosis in my b<lby's blood 
Test for HTV l!.~~~~ bCl~ b!.Qg.d 
[ 3. Reseal·ch staff W~,llts to enroll m~ baby into the reseal'cll stu~I)~~ ~hatj.!l.':.I_~?):. 
, Tllel' C{TII col/l'CI blood/i'olll /lI,~ baby 
The, call inject Ill" babY with BeG 
I The; C<ln te~t my b<lby for TB or HIV ; 
15~ OW 6%) 
:>5 (18:>%) 
2 ( 1 1%) 
115 (609%) 
~o (21.1%) 
-----1 
:>~ (180%) 
s. The most common .-isl .. inyohed when blood had heen collected f,·om IU~ bab~ is (n=192): 
,\11- /loIn' 1I1l1,1' sl/l!i!r 1'l'ly slighr scarrillg alld SOllie oo:ill,'< 152 (79.2%) 
My baby can become infected with TB or HIV :>5 (18.2%) 
My ba~£ln 109se too mllch blood 5 ( 26%) 
6. Th~~eIlefits a~' ailable to me and I1I~ ba~~Jol·l!..al·.!ic},l'_a .. .i'I~ i.I!. ~h~!!!.dy are (n=!9!): 
I 
M~ bab, "ill be protected Claainst TB 
Tllere are 110 i/lll/ll'di(){e belletirs 
I My baby and I " 'ill get better treatment at clinics 
7. If I didn't want to J~.al·tic!rate in this stud), I could withdraw and fn=189) 
,\h hohy illld J \rOllld sl~Ui!r 110 loss ar 0/1 
I My babY and J "ill be treated differenth b, research and clinic staff 
r M;' b~,~; .and J. "Oll!(~ ~ (ielife~ ~c~~ss- to h~llii~'sel'\-:-i~s at this clinic 
8. M~ bilb~'s .l!e .. sonal details will ne~er !!! linked with her blood because (n=191) 
YIIIII/Jers 11irll harcodes 11-;/1 be IIsed 10 keep Moods alloll~lIs 
Highly trained research staff "ill keep information secret 
Clinic staff will be sure 1I0t to gi,e information to the reseCH~..!! sti!..fL 
l 9. The ~lloo~l o_f ,!!.~., h.~_~~' that willbe f.1"(,-~~n it,I~~! ~~!.~red win be used (n=187) 
t For orller resrs cOlleenllllg 1!.~{2recrioll ogaillsr TR 
For all kinds of research in other cOllntries 
----- - --. 
For HIV testing 
16 The questions refer to the Immunology Study, See pages 25 to 28 for explanation. 
n (51:>%) 
70 (:>6.7%) 
2:> (12.0%) 
12:> (65.1%) 
---. ---~- . ~ --
n (2~9%) 
- - " " - -- "--- -
L9 (100%) 
1~0 (7:>.:>%) 
~O (20 .9%) 
11 (118%) 
1 1 55 (8 ~, 2,~o ) 
t 2lJ(15 .5%) _ :> ( 16%) 
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Table Vllb: Results of quality of informed consent assessment: 
Cross-check section 17 
------r -
Yes % No O/h Don't 
know % 
10. The~rocedures done on my bab~' in this stud~ al·e 
. --'-Saf~ a~ld-P0ctic~lIy 113flllless -----; 
Dangerous and harmful 
11. My baby's blood is goi!!g~~e used to 
Help de\elop a blood test for TB 
Determine \\hether my baby has TB 
I 12. My bab~"s name is "Titten on all tbe blood tubes 
riG. I was eOI·olled ill the stud, in un borne language* 
~s questi'~n w~s not pari-;;ftbe a ; eement ~nalysis .. 
I 
r 
88.5 7 .~ 
() 2 8./ . ./ 
1'0 i 8.9 
55.2 38.5 
19.8 73.-1 
9./.8 ~.6 
Table Vllc: Results of quality of informed consent assessment: 
Understanding section 18 
.. . --
-
._-- --
-
~ 2 
!)~ 
8.9 
-
G.~ I 
-
6.8 
1.6 
[ 13. I aOI·eed to eUI·olI nn child iu this stutl,Y because 
-j '" . -T I M\ child might get bett er treatment ~~8 52.1 :;.1 
--+- ~.7 1 I \yant doctors to help learn more about TB 88.5 6,8 
[ u. I'\'e decided to enroll my bab\' in the stuth I E\en though my baby '~Yill r~ceiH no e:'\t;'a treatment 73 . ./ I!). ~ 7 ~ 
" 
Bec,lUse I kne\\ T \\ouid recei\e a toiletries hamper I uo 8u T t 6 . ~ 
[ 15. _!L!!l'~ ·b'a~.I..E;ets il!lruise.lrom th~~IOQd test, i s~o-~J; I 
T 
.. 6~8 1 Contact the police 5.7 87.5 
.. -
~peak to the nl1('se at the clinic ! 68.2 ~O 7 1.1 ~to the doctor at his pri\ 'ate surgery 22.~ 00.2 ll . .t 
t---
17. If I was ghen tbe choice to l)articil'ate again. I would ~ 90.6 ~, L Cd 
Table Vlld: Results of quality of informed consent assessment: 
Health rights section 
I 18. Wbich of !!!.e following rig hts al"e .I)rotectetl iu the South African constitlltion'!_ 
access to health care I 85. <) 5.7 8.:> 
conceal ment of pri\ClIe Wf()'fffiCll ion" ) t---G 7 7 
freedom from bodd\ harm 58. 3 
17.2 15.1 
20.8 20.8 
1 Free health care to all - -[ fr~~o1l1 ()Lchoice 891 11 5 5.2 .t,2 1 __ 6~ 7 ~ 
17 The questions refer to the Immunology Study. See pages 25 to 28 for explanation. 
18 The questions refer to the Tmmunology Study. See pages 25 to 28 for explanation. 
19 The actual wording in Afrikaans was "geheimhouding van privaat inligting", In Xhosa it was 
"imifihlelo yencukacha zako". 
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Figures 7 and 8 give graphical illustrations of the recall and understanding 
scores obtained by participants. 
Figure 7. Recall of information (n=192) 
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Figure 8. Understanding of information (n=192) 
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P O. 
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1 77 (70. 28 (25 7 4 3.7 
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hp!'lllh rights knowledge 
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same two significant 
experience of research nurse 
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recall test 
Also, consent 
research experience resulted In 
an at least 7 compared to nurses with 
The logistic re~lressio 
greater 
were 01 
scores than those younger 
were started with as 
Table XIII: 
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were Removmg some 
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Health rights assessment 
The results of the five questions that were asked to assess the knowledge of 
health rights as contained in the South African Constitution are illustrated in 
Figure 8 below. Most participants knew about the constitutional right access 
to health care (86%) and freedom of choice (89%), and only some knew 
about the right to be protected from bodily harm (58%) . Only 11 % knew that 
health care was not free for all, and only 17% had the question about 
confidentiality of private information correct. 
Figure 9. Illustration of knowledge of health rights as contained in the 
South African constitution (n=192) 
I I I I 
Freedom of choice 1 
Access to health care I 
Freedom from hann I 
Confidentiality I 
Free health care to all I 
o 20 40 60 80 
Correct answers (%) 
The overall score for health rights was not linearly correlated with either the 
recall or the understanding assessment (Spearman's correlation coefficient 
not greater than 10 .101 and p = 0.9605 and 0.4117, respectively). The 
individual scores for each of the health rights also had no association with 
the recall scores, and all but one of the understanding scores. The 
knowledge of right to freedom of choice was significantly associated with the 
understanding score (OR = 2.59, 95% CI = 1.06 - 6.34). 
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Other findings 
• Table XIV contains the results of the logistics section. The majority of 
participants (74%) took between 10 and 20 minutes to complete the 
questionnaire. A small number (12%) took longer than 20 minutes. A 
total of 21 (11 %) of participants required a substantial amount of 
assistance with the questionnaire. Eighteen (78%) of those who 
required excessive help took longer than 20 minutes as we". 
Table XIV: Results of logistics section 
The length .. 2f time it took to complete tbe questionnaire wa~ n= 192) 
1 Under 10 minutes 
Between 10 and 20 minutes 
27(14.0%) 
142 (740% 
23 (120%) 
.... 
Longer than 20 minutes 
The amou nt of assistance given by study staff to complete the questionnaire was (n= 19~) 
I Minimal, only clarifications re.CJuired here and there 73 (380%l 
[
Moderate 98(510%) 
Substantial, the participant required much help 21 (110%) 
• Participants obtaining a high score (75% and greater) for the recall 
section were 3.15 times (95% CI = 1.21 - 8.13) more likely than those 
obtaining a lower score to take less than 20 minutes to complete the 
questionnaire (Table XV). The association is even stronger between 
high recall scores and the amount of help required (Odds ratio = 4.83, 
95% CI = 1.63 - 14.24). High scores for the understanding test 
showed no significant association with either of these factors. 
Table XV: Quality of informed consent scores in relation to time taken 
and help required to complete the questionnaire 
Taking less 
than 20 minutes 
No substantial 
help required 
High scores (75% and 
greater correct) for the 
recall test 
OR 95% CI 
3.15 1.21 - 8.13 
4.83 1.63 - 14.31 
High scores (75% and greater 
correct)for understanding 
test 
OR 
2.12 
2.08 
95% CI 
0.89 - 5.03 
0.85 - 5.10 
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• The results of the agreement check between four questions in the 
recall section and corres ing questions in the "Yes/No" section are 
tabulated underneath. e XVI high total 
i.e. 60 - 73%. sties were, however, low. The 
answers to questions of the purpose of the Immunology Study had 
the least agreement (Kappa statistic = 0009). The best agreement was 
found with the confidentiality (K = 0.300). 
two fur .. '''" q ing 
Total Ch~oce rcement 95% Confidence 
Agreeluent (Yo agreell!11ent K Interval 
Pu rpose 69 8 69.5 0009 -0132-0150 
l'rocedure 60.9 57.6 0.078 -0.026 - 0 182 
Risks 72 9 70.1 0.096 -0.044 - 0.234 
Confidentiality 72.4 60.7 0.297 0.155-0.438 
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Appendix A' Standard Operating procedure: Immunology Study Consent 
STANDARD OPERA T1NG PROCEDURE NUMBER 2 
Description: Consent, Clinical evaluation, blood collection and transport 
2 Staff Involved: Study Phlebotomy Team / Courier Drivers 
3 Principle: 
The University of Cape Town (UCT] and a group of overseas researchers, with the approval of the Boland 
Overberg Regional Health Department, are interested in studying the immune response to BCG vaccination 
in small infants. The aim of this immunology study is to determine whether we can measure with a blood 
test whether the vaccine has either protected, or has not protected, that infant against tuberculosis. Infants 
who have been enrolled into the larger randomised controlled trial comparing two roules of giving BCG 
vaccination (the "BCG Trial") may also be enrolled into this immunology study. 
Blood will be collected from 8-14 week old infants that had been vaccinated with BCG at birth. This blood 
will be transported to the Groote Schuur Hospital BCG laboratory (Cell Bank) in Cape Town, where white 
blood cells will be isolated and stored in a freezer for immune tests at a later stage. Some blood will 
immediately be processed at the clinics to start measuring the immune responses caused by the vaccine 
while this blood is being transported to the Cell Bank. 
This is a multidisciplinary trial and each member of staff will have specified tasks, either in the 
laboratory/cell bank or in the clinics. Careful co-ordination and team work ill ensure smooth running of 
the study with minimal inconvenience to parents and infants and ensure that the blood samples get to the 
Cell bank for processing as soon as possible. 
4 Contact/Telephone numbers: 
Designation Name Office Home Cell 
Field Manager 
Medical Officer 
Principal Investigator 
Driver 
5 Preparation - instructions for phlebotomy team 
5.1 Ensure before leaving each day that you have: 
5.1.1 The "bleed list" (list of infants due to present for blood taking for that day.) 
5.1.2 Adequate suppLies of the consumables listed beLow for that day's bleed. 
6 Venue 
6.1 Blood will be collected from infants at the fixed clinic nearest to their homes by members of the 
phlebotomy team. Phlebotomy clinics will generally begin as soon as the clinic opens, usually at 
08hOO. 
7 Reception 
Instructions to study nurses and nursing assistants 
7.1 Check each infant's Road to Health Card (RTHC) to see that there is a Study label/number attached 
inside and an orange coloured study sticker on the outside. 1f the infant has a study sticker and 
number, go to 7.3 below. 
7.2 If a infant arrives with no RTHC and no number: 
7.2.1 
7.3 
7.4 
7.4.1 
Contact the study office to enquire whether the wfant is on the database and if so what the infant's 
study number is. 
Hand-write the study number onto 5 blank identification labels. 
If the office has no record of the infant: 
Take down the infalIt's details (surname. first name, date of birth) and give another date. 
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8 Consent 
8. I about the its risks Consent is an 
;Jnd benefits. All written informed consent is just ant step in this 
process. 
8 1 nurses will obtain writti.:n informed consent. 
8 First counsel the infant's parents in a group about the 
84 Then consent for in the from the This part of 
consent must be done in a in a room, away from the rest of the 
infants' mothers/fathers. If such a room does not then the individual counsell and of 
the consent must be done the room llsed for the of the blood. 
8.) Al ow sufficient time for the infant's mother/father 10 read the information brochure and consent 
form and to have any answered in full. 
8 0 ObUin the of either the motller or the father or both parents. All 
Ihe spaces 
8.7 Get a third person the 
8.8 S and date the "i statement" 
8 9 Give a copy of the consent to the to 
into the infant's clinic records. 
9 el to take part in the 
9.1 For each infant ask about: 
9 .. 1 
9.1.2 admission to 
Current or recent illnesses 
Current or recent medications 
to as wi tness. 
This should be taken home 
9.1.3 
9.14 
9.1 :i 
91.6 
Cont:.\ct with a person from tuberculosis or to be 
9 1.6.1 
9.1.6.2 
9.1.6.3 
9.1.64 
and / or symptoms of tuberculosis in the infant. 
Loss of 
sweats 
Fever 
to be dated in 
the parents not 
from tuberculosIs 
9.2 Make an assessment of the el 
9.2.1 
of the infant to Exclud(; the infant if 
for routine childhood 
vacei nations 
9.2.2 contact with or of tuberculosis. If unsure. contact the 
medical officer or 
10 Blood 
10.1 Leave the incubator 
maximum thermometer in the 
the incubator. 
into the of the car. Leave a 
incubator. This will be reset before the first 
minimum -
men is 
\0.2 the mini··incubator in at the wal in the eonsul room of the elinic 
I J Wipe down all work surfaces wirh 100% EtOH. the 2mL Sarstedt tubes with thE; 
in their cooler box until are needed. When needed remove onl} I set of :I at a time: 
leave the remainder in the cooler box Wear when the sarstedt tubes. Chel'k the 
in the cooler box icall) to make sure that it is not ,lbove 8 C. 
4 Identification List form" Form 0 n bal pen. Attach a 
identification label and write the name down on the form. 
10) again to the infant's that: 
.5.1 B oDd wIll be taken from the best available which will be either a vein or a neck 
10 J. 
10 j J 
when b oDd and use a fresh pair per donor 
ml of blood will be taken. 
A maximum of three at \\ ill be made to obtain the blood. If it proves 
to obtain a men from an infant on a lar and the infant is 
Jess than 4 weeks the infant's may be to bring the infant to the following 
session at that clinic if her/his age will be less rllan 14 weeks at tllat tim{; 
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10.0 Inform the may at any time ask the team to the and wlthdra\\ the 
10 7 in the mini-incubator is more than 30°Celsius If not, wait untjl it is. 
Reset the min.lOlax. thermometer at this stage. 
10.8 Two will collect the one will hold the infant and one will take the blood. A 
nurse and assistant will 
10.9 Do not ask the infant's parents to of with 
the infant whilst the blood is taken. 
10.10 Both the nurse and the assistant must on 
10.11 Write the first 3 leiters of the infant's surname on 4 of the infant's identification 
the black pens the and care nol to write over thlJ 
bar code area. I the infant's surname consists of more than one word e.g. "van der Merwc", "du 
Plessis", then \\ rite the first 3 letters of the main word e.g "MER" or "PLE" in the 
above. 
10.12 Clean the skin wilh an alcohol swab 
10.13 Draw lOml of blood trom the best vein e.g. in the antecubital a 10mi 
with a 23 gauge needle attached. 
10.14 invert the synnge 10 times Remove the needle and discard in a container 
10. 5 
0.15 I Unscrew the top of the sarstedl tube and the side up on the suface 
Carefully the blood into the 2mL Sarstedt tubes. Avoid the inside of the lube with 
the fill the red tube up 10 the 1.0mL mark and lhe other Iwo tubes 
up to the O.25mL marks. 
10.15.2 Vortex each 20lL Sarstedt tube. 
10.15.3 identification stickers: 
Label the set of sarstedt tubes for the WBA with the white 
Label the set of sarstedt tubes for the RNA isolation with the 
identirication sticker . 
. 15.4 PI(lce the 2mL Sarstedt tubes in lhe mini-incubator. 
(). 16 -'-'-'."-'-'-'.b..."'--'-'-"'-""-'-"'-'-'.!.'b-'~-"'-''--'--~~ 
10. 6.1 Clean the rubber in the CPT tube witb an alcohol swab. 
10. 6.2 Put a 19 gauge needle onl0 the and allow the vacuum to draw the blood InIO one 
8mL vacutainer CPT tube as follows: 
.16.2.1 Place; the tube on :.l tdble. 
10. 6.2. Remove the hand th;.!1 pL.lces IIH tub..: there. 
10. 6.2.3Place the of the I 'lG S) nL~dle on til..:; rubber "i>urfJc(; of the CPT PRIOR TO TOUCHING 
THE CPT AGAIN. 
o 16.2.4WHEN THE NEEDLE IS ON THE RUBBER SURF \ STABILIZE THE CPT TUBE WITH 
THE OTHER HAND. 
10. 6.25 content'S into the tubl.: .\110\\ th.:: \.l(;uum to draw thl; do not put pressure 
on the 
10.17 Put a idcntiiic:nioll stickl:r on the CPT tube 
10 18 Reset the min··max thennolllet.::r in the CPT tube cont:liner 
the first CPT tubf.: 
10.]9 Place (he CPT lube mto the.: rack in the CPT cOl1!.Jincr. 
cooler before in 
0.20 The temperature in the transport .:;ontainer mut.t b..:. mdinlain.A b(;!w.:;~n hi and 25°C. The of 
this box is tl1crdon:: at th,' dis~ r.::tion of the 1<.'-'''-'''-''''''-''''-'-'-'-'---''_''-'''-='-'-''."'''-''.'''-.'-
10.21 ~==~==~~=~~~~~~==~~==~ 
10.21. 1 First fil I the 2 mL Sarsted t tubes 10 the followi ng order Red Whitt; Blue 
0.7.1.2 Now allow the remainder of the blood to be drawn ioto an 8ml CPT tube. 
10 22 After blood from ca..;h infant 
10.22.1 Note the lime of blood on Form 3.0 . 
. 22.2 Fill in the details 
2) I.e in mini-incubator 
in Sarstedt-tubc cooler box. 
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1 L Incentives: 
11.1 Distribute the incentives to the caregivers and their infants (details in SOP I). 
11.2 Fill in the incentive list (name, study number, clinic and date for each infant bled and gjven an 
incentive.) The infant's parent/guardian must sign for the incentive. 
12 Storage And Transport Of Tubes With Blood· 
12.1 Before leaving the clinic, check the specimens for number and integrity. 
12.2 Transport all tubes upright, protected from sunlight. 
12.3 They musr all reach the laboratory wilhin five hours from the time the first sample was taken. 
12.3.1 Transport polypropylene tubes in the portable incubator at 37°C. Before transferring the specimens 
from the plug in mini incubator to the portabLe; incubator. make sure that you reset the minimum 
maximum thermometer in the portable incubator. 
12.3.2 Transport CPT tubes in a Coleman cooler box, packed to maintain the temperature between 16 and 
25°('. 
12.4 Transport the bloods back to the Worcester (Brewelskloof) project office. 
12.5 At the project office: 
12.5.1 Check the; current temperatures of the incubator and cooler boxes. 
12.5.2 DO NOT reserrhe minimum maximum thermometers at this stage. 
17.5.3 If one or more of the temperatures is out of range. phone the laboratory for advice (021-406-6149) 
before proceeding any further. Any problems with equipment must be reported to the Laboratory. 
12.5.4 If the ambient temperature is more than 25°C, place the portable incubator in a large polystyrene 
cooler box surrounded by ice packs before giving it to the courier. 
12.5.5 Unload the incubators and cooler boxes from your vehicle and load them into the courier vehicle 
intact I as is. Transfer them in their incubators I polystyrene containers to the courier's vehicle. 
Make sure that the portable incubator is pLugged into the cigarette lighter socket in the courier 
vehicle and that the indicator light and temperature display show that it is working. 
12.5.6 Note that all the details on Form 3.0 are completed before you or the courier driver sign the form. 
12.5.7 The courier driver will sign for the forms and the bloods in the container. 
12.5.8 Note the name of the driver and the time s/he leaves the project office. 
12.5.9 Phone the laborMory (021-406-6149) and inform them thM the specimens have left. 
12.5.10 Give the completed "Daily temperature record sheet for clinic incubators" forms to the area 
manager for checking and subsequent filing at the Worcester project office. A 10% sample of these 
forms will be audited once a month by the study internal monitor and any violations reported to the 
medical officer and laboratory. 
12.5.11 Cleaning of incubators: 
At the end of each phlebotomy session ~wiQ!;. down both the portable and mini-incubators with 100% 
EtOH. 
IJ Safety Issues: 
13.1 Instructions To Nurses And Courier Handling The Specimens -
13.1.1 If you are injured by a contaminated or potentially contaminated object such as a bloody shard of 
glass from a broken test tube: 
13 .1.1. 1 wash the affeckd part immediately with soap and water. 
13.1.1.2 Study staff and Courier: contact the project medical officer, Dr. Tony Hawkridge. inllllediately 
and refer to the needlestick injury SOP. 
You are welcome to contact Dr. Hawkridge for advice if necessary (082 550 9002) 
13.1.2 In the event that a tube or tubes of blood ale broken and blood is spilt: 
13.1.?.1 Immediately pour sodium hypochlorite solution (Bleach) onto the brohn tube and any leaked 
blood. 
13. 1.2.2 Note the details of the incident and the identification number(s) on the affected tube(s) Oil a 
"specimen incident" form (appendix I). You should have a supply of these forms with you 
whenever you are dealing with study specimens. Submit the completed report to the Worcester 
Project office as soon as you can. 
13.1.2.3 Inform the study area manager, Mr. Minnies, and the laboratory technologist in charge, Mr. 
Gelderblom. ot the details by telephone as soon as is possible. Contact details are above under 2. 
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Appendix B: Immunology Study Consent form 
THE UNIVERSITY OF CAPE TOWN 
CONSENT FORM 
Revised March 4,2002 
Protocol title: 
Immune correlates of vaccination-induced protection against tuberculosis. (Initial enrollment in case-
control study.) 
A. DoGlors and nurses at the University of Cape Town and a group of overseas researchers 
are involved in research to determine how best to prevent tuberculosis in children, u~ing 
BCG (the vaccine that prevents tuberculosis, especially severe tuberculosis). This study 
involves research In this specific study the doctors will measure in infants' blood how the 
immune system has responded to routine newborn BCG vaCCination The researchers hope 
to identify a blood test that will inform them whether the BCG vaccination has protected, or 
has not protected, a specific child against future tuberculosis disease. 
B. The expected duration of a child's participation in this research study is 1 day (only the 
enrollment day when my child will be evaluated and blood will be collected from him/her). 
However, as explained below, in the first 4 years of the child's life, if he/she develops 
tuberculosis disease, or is chosen as a healthy matched control subject for those children 
who develop tuberculosis, he/she may participate in the study for another day. At this time 
a separate written informed consent will be taken from t he parent/guardian. 
C. The procedures to be followed are: 
All children are immunized with the BCG vaccine soon after birth. At the 10 week routine 
childhood vaccination visit to a district clinic, 10mL (2 teaspoons) blood will be taken from 
the child, after a nurse has taken a brief history and has examined the child. This blood will 
be stored (processed and frozen), and may later be used to measure how that child has 
responded to the vaccine. 
Blood will be taken from approximately 6,000 BCG vaccinated children to be enrolled in 
this study. 
Many of the children enrolled in this study will be exposed to an adult who is spreading the 
tuberculosis bacterium through his/her own disease. Some of these children will become 
infected and develop tuberculosis disease The research team estimates that about 400 
enrolled children will develop tuberculosis and will assume that the BCG vaccine has not 
protected these children. 
However, not all children who are exposed to and infected with tuberculosis bacterium will 
develop disease. Their Immune systems are somehow stronger and fight off disease. The 
research team will assume that because these children have not developed tuberculosis 
disease, the BCG vaccine has protected them. They will be called "matched control 
subjects" by the researchers. 
Once children with tuberculosis, and matched controls, have been identified, the 
researchers will retrieve the blood stored taken from these children when they were 10 
weeks old Immune responses in this blood will be compared between children who 
develop tuberculosis (not protected by the vaccine) and those who do not develop 
tuberculosis even though they have been infected by the tuberculosis bacterium (protected 
by the vaccine, the "matched control subjects"). Two matched control subjects will be 
included in the study for each child with tuberculosis disease. In the event of a child 
developing tuberculosis, or if a child is selected as a matched control subject, the child will 
have an HIV blood test at that time. 
At 10 weeks of age, doctors cannot predict who will develop tuberculosis and who will be 
infected with the tuberculosis bacterium without developing disease. Therefore. to later 
have blood samples available from all these children, blood must be collected at 10 weeks 
of age from all 6,000 children enrolled in the study. 
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Blood from each and every child enrolled in this study will therefore not be used for tests in 
this study, particularly If Ile/she does not develop tuberculosis, or is not chosen as a 
matclled control. Nevertheless, blood will still have been stored from all children. The 
rosearchers may wish to use this blood for other infectious disease research studies. A 
code will be used to identify children's blood: his/her name will never be revealed. There 
will be an opportunity at the end of this document for parents/guardians to sign whether 
they wish to allow the researchers to use their child's blood for any infectious disease 
studies other than this study, if the stored blood is not used for this study. If a 
parent/guardian does nof allow for the blood to be used for other studies, blood will still be 
collected from that child; however, it will be discarded after the study has been completed 
o Tile possible discomforts and risks attendant to this study are : 
The risks of taking blood from children are small, particularly as small amounts of blood will be 
taken . Slight pain or bruising can occur when blood is sampled ; very rarely , the skin area from 
where the blood was taken may become infected or bleed a little. The research team will take 
precautions to prevent these complications . 
E Ttll'! benefits that a child might reasonably expect from participating in this study are : 
There is no benefit for a child in participating in this study; rather, the information from this 
study may help doctors in future to predict whether the BCG vaccine given to a specific baby will 
protect him/her against tuberculosis disease, by doing a blood test measuring immune responses . 
F . The alternative procedures, if any, that could be considered : 
Not to participate in the study . 
G . A copy of this consent will be handed to the parent/guardian to keep . Records connected 
with a child's participation in the clinical investigation will be kept strictly confidential. No 
parent/guardian or child's name will not be revealed in any publication that may arise from 
this study . 
H. This study does not involve an investigational drug. BCG is a routine vaccine of childhood. 
I. Opportunity will be provided for questions and discussion of the content of this document 
prior to Signing of consent. If any questions concerning the research conducted remain, 
Professor Greg Hussey may be contacted at 021-685-4103 . If any concerns arise about 
any child's rights as a research subject, the University of Cape Town Research Ethics 
Committee rnay be contacted at 021-406-6492. Any participant is free to withdraw consent 
at any time without penalty or loss of benefits to which a child may be otherwise entitled. 
The resei:Hl.:h team may also terminate the study , or any subject 's participation, at any 
time . 
J . In the event of a parent/guardian believing that participation in this research study has led 
to injury of a child, the parent/guardian may contact Professor Greg Hussey at 021-685-
4103 to identify the medical resources which are available to the child and to assist the 
child in obtaining appropriate medical care. 
I have read this document and understand its content. I have had the opportunity to discuss 
the study and its procedures , and questions that I may have, with the research staff. I hereby 
voluntarily consent to voluntary participation of my child, , in this 
study and to allow the treatment and procedures described above to be performed on my child . 
Name of Parent IGuardian -
pi ease pri nt 
Signature or 
thumb print 
Date 
Name of witnesS(study personnel) ----·------s;g-nature-----------Date---
please print 
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For use if a thumb print was used 
I herewith confirm that the ink mark above is the right hand thumb print of the parent/guardian. 
Name of independent third person 
please print 
Signature 
I also understand that not all the blood that is stored will be used in this study. 
Date 
I consent to the stored blood from my child, if not used for this specific study, to be used for other 
infectious disease research studies. 
Name of Parent IGuardian -
please print 
Signature or 
thumb print 
Date 
I do not consent to the stored blood from my child, if not used for this specific study, to be used 
for other infectious disease research studies. 
Name of Parent IGuardian -
please print 
Name of witness (study personnel) -
please print 
For use if a thumb print was used 
Signature or 
thumb print 
Signature 
Date 
Date 
I herewith confirm that the ink mark above is the right hand thumb print of the parent/guardian. 
Name of independent third person 
please print 
INVESTIGATOR'S STATEMENT 
Signature Date 
I have offered an opportunity for further explanation of this procedure to the individual whose 
signature appears above. 
Name of InvestIgator -
please print 
Note: 
Signature Date 
The subject must be given a copy of this consent form. A signed copy must be filed in the 
subject's medical record in the Medical Records Department. 
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Appendix C Standard Operating Procedure : Consent Study 
I QUALITY OF INFORMED CONSENT: Standard operating procedure 
Applied to: 
Location 
Materials: 
Professional Nurse (PN) conducting the Exit interview 
Clinic where Immunology Case control stuJy enrolment takes place 
Consent forms in appropriate language 
Questionnaire in appropriate language 
Closed envelopes containing R50 each, with participant's name 
Environment.Chair & table I tablet to write on 
Privacy 
Help to hold baby 
GUidance and assistance with questionnaire as required 
Procedure 
1. Following initial enrolment into the ICCS, mother referred to QCJIC 
2. PN explains purpose of tht! survey 
3. PN asks If willing I able to stay & participate 
4 PN goes through consent letter 
5. PN asks mother to sign consent 
6. PN faci I itates conduct of the interview: 
(a) Explains layout of questionnaire 
(b) I\sslStS participant to complete demographlcs 
(c) Assists participant where necessary to interpret questions 
(d) Checks if all questions were answered at the end 
(e) Record duration & difficulty details 
(f) Checks participant answers against correct answers 
(g) Correct participant understanding where necessary 
(h) Signs and dates questionnaire 
7. PN thanks mother then hands her the reimbursement after she signed a receipt 
8. PN completes form and submit to office for capturing 
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Appendix D· Consent Study questionnaire (Engli§hl 
Serjal number 
QUALITY OF CONSENT EVALUATION QUESTIONNAIRE ,---[ _J 
~Ud Participanl - -----_._------- ---, y baby T-nu mbrr 
icipant 
of birth 
Pan 
date 
Dal 
IOle 
c of 
rvie\\ 
-
- ._ '---_. _ -
name 
Participant 
address 
Langmlge 
spuhn at 
home eg A 
for 
Afrikaans 
-
I 
- - - .-
-l~ Eg 
Grad 
St 8 
SIan 
";,~ G ~ for 
e S or 
for 
dard ~ 
Tel 
Cell 
A. Select the ONE optIOn that best completes the statement r_~arding the study..,Y.Q1! 
were asked to consent to earlier today (Correct answer in red - for illustration only. 
For survey all options will appear identical in print.) 
1. 1 have been asked to attend the clinic today so that: 
(a) My baby can reG'eive expert treatmen/_ 
(b) My baby cun participate in a research study 
(c) My bahy wn receiw routine health care 
'), The purpose of the research study is to: 
(a) Test for protection against tuberculosis in my bahy's blvud. 
(b) Testfor tuberculosis in my baby's bluud 
(c) Testfor HIV in my baby's blood 
1 Research staff wants to enroll my baby into the research study so that 
(a) They can lest my baby for TB or Hi V 
(b) They can collect blood frum my baby 
(c) They can inject my btiby with BeG 
4 The total amount of time my baby will be expected to participate in the study is: 
(a) 2 tu 3 years 
(b) 8 to J -1 weeks 
Ie;) 1 day 
':i. The most common risk involved when blood had been collected from my baby lS 
(a) !vly buby can become infected with TB or HIV 
(b) My baby may suffer very slight scarring and some oozing 
(e) My huby can loose too much blood 
6. The benefits available to me and my baby for partIcipating In the study are 
(u) There arc no immediate bemjlts 
(b) My baby w;t/ be pruJected agairls/ TR 
(c) My baby and I will get bc>tter fr.!afment at clinics 
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7. If I didn't want to participate in this study I could withdraw and 
(a) My baby and I would be denied aGress to health serVices at this clime 
(b) My baby and 1 wiil be treared d~fferently by rt:semch and clinic staff 
(c) My baby and 1 would sl~ffer nu loss ut all 
8. My baby'5 personal details will never be linked with his / her blood because 
(a) Numhers with barcodes will be used to keep bloods anonymoll .... 
(b) Highly trained research stall will keep information secret 
(c) ('linic staJ/will be sure flot to give information to the research staff 
9. The blood of my baby that will be frozen and stoled will be used 
(a) For all kinds of rese~trch in other countries 
(b) For HI V testing 
(c) For other tests concerning protection against lB 
a. Statewhether yoU ~gree with the statements belQW bv ticking off the appropriate box 
nl~xt to each _statf:ment 
Yes No 
10. The prol:edures done on my baby in this study are: 
(a) Safe and practically harmless... . ... "'" . U 
(b) Dangerous and harmfu I. . .... .. .... 0 
11. My baby's blood is going to be used to 
(a) help develop a blood test for IB.. 0 
(b) determine whether my baby has TB... 0 
12. My baby's name is written on all the blood tubes.. 0 
13. I agreed to emoil my child in this stUdy because 
(a) My child might get better treatment. .................. . 0 
(b) 1 want doctors to help learn more about IB.... . .. 0 
14. I've decided to enroll my baby JO the study 
(J.) even though my baby wil I receive no extra treatment Il 
(b) because I knew I would receive a toiletries hamper 0 
15 If my baby gets a bruise from the blood test, I should 
(a) Contact the police......... ......... 0 
(b) Speak to the nurse at the clinic...... 0 
(c) Go to the doctor at his private surg.:::ry... 0 
16. I was enrolled in the study in my home language......... 0 
17. If I was gIven the choice to participate again. I would. U 
18. Which of the following rights are protected in the 
Suuth African constitution? 
(a) access to heal th care............... ........... . .. . .... 0 
(b) conceal ment of private information.. .. .. ................. 0 
(c) freedom from bodily harm. ... ...... .. ........ [J 
(d) free health care to all ......... " ...... ......... 0 
(e) freedom of choice .............. "" ' '' ' '... .. . ..... " 0 
o 
o 
J 
o 
o 
o 
o 
[ ] 
o 
o 
J 
o 
o 
o 
c 
o 
u 
o 
o 
Don't 
know 
o 
o 
o 
'] 
o 
o 
n 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
[) 
o 
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If contradictory or exploratory comments were made, please note the question number and 
record the details in the adjacent space, Also ask if there are any questions and record 
details . 
Question Answer Correct? Question Answer Correct? 
1 B 13b 
2 A 14a 
3 B 14b 
4 C 15a 
'--
5 B 15b 
6 A 15c 
7 C 16 
8 A 17 
9 C 18a 
lOa Yes 18b 
lOb No 18c 
lla Yes 18d 
lIb No 18e 
12 No 
13a Total 
The length of time it too\..: to complete the questionnaire was : 
(a) Under 10 minutes 
(b) Between 10 and 20 minutes 
(c) Longer than 20 minutes 
.-
Yes 
Yes 
-- - '- ' 
- ---
No 
Yes 
No 
Yes 
The amount of assistance given by study staff to complete the questionnaire was : 
(a) Minimal, only ~larifications required here and there 
(b) Moderate 
(c) Substantial, the participant required much help 
Name of Consenter of Case Control Study 
(Signature of research nurse) (Date) 
(Signature of data capturer) (Date) 
--
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Appendix E : Consent Study questionnaire (Afrikaans) 
~c ri ~ 1 Hlllll b a 
"QllALITY OF CONSENT" EVALUASIE VRAAGBRIEF 
Study baby Participant 
T -number name 
Participant Participant 
date of birth address 
Date of Lang~agc- !---- - - --I Education I Tel 
interview spoken at Eg _ G ~ for 
hOllle eg A Grade 8 or --
for J SI ~ for Cell 
Afrikaans _'---_____ §tandar:.~ 
- ---- -- - - ----
AKies die een opsie wat die beste pas by die vraag oor die studie , soos IY dit verstaan~ 
die toestemming wat jy vroeer vandag gegee het. 
1. Ek is gevra om die klinit:k by tt woon sodat 
(a) My baba spesialis behandeling kan kry . 
(b) My baba kan deelneem in ' n navorsing studie . 
(c) My baba roetine gesondheidsorg kan kry . 
2 _ Die doel van die studie is om te 
(a) Toets vir beskerming teen IS in my baba se bloed 
(b) Toets vir TB in my baba se bloed . 
(c.) Toets vir HIV in my baba se bloed. 
3 . Navorsing personeel wi I my baba Inskryf in navorsing studie sodaL 
(d) Hul1e my baba kan toets vir TB of HIV . 
(IJ) Hulle kan bloed trek by my baba. 
(c) Bulle my baba kan in ent met BCG 
4 . DIe tyd wat my baba sal deelneem aan die studie is : 
(a) 2 tot 3 jaar 
(b) 8 tot 14 weke 
(c) 1 dag 
5 . Die mees algemene risiko by die trek van bloed by die baba is : 
(a) My baba kan besmet raak met IB of HIV . 
(b) Effe kneusing en bloeding mag voorkom . 
(c) My baba kan bale bloed verloor . 
6 . Die voordeel vir my en my baba om deel te neem aan die stud ie is 
(a) Daar is geen onrniddelike voordele nie . 
(b) My baba sal beskerm wees teen TB. 
(c) My baba en ek sal beter behandeling kry by k.Iinieke 
7 . As ek nie wit deelneem aan die studie nie, kan ek onttrek en : 
(a) My baba en ek sal toegang geweier word by hierdie kliniek 
(b) My baba en ek sal anders behandel word deur personeel. 
(c) My baba en ek sal geen verlies lei nie 
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8. My baba se persoonlike inligting sal nie gekoppel word met sy/haar bloed nie, want 
(a) 'n Nommer met 'n strepleskode sal gebrUlk word om bloed naamloos te hou 
(b) Hoogs opgeleide naVOI sing pel soneel sal informasie geheim hOll. 
(c) Kliniek personeel sal nie informasie gee aan navorsing personeel nie. 
9. Die bloed van my baba wat g~vries en gestoor word, sal gebruik word om 
(a) Vir allerhande tipe!'; navorsing in oorsese lande. 
(b) Vir HIV toetse. 
(c) ViI ander toetse oor beskerming teen TB wat nog nie bekend is nie. 
B. Dui \I antwoord aan deur die btokkie af te merk waarmee u saam stem. 
Ja Nee Weet 
10. Die pi osedures gedoen op my baba in hierdie studie is: 
(a) Veilig en eintlik skadeloos..... . .............. . 
(b) Gevaarlik en skadelik . .. . . .. .. . 
11. My baba se bloed gaan gebruik word am 
(a) 'n bloedtoets te ontwerp te~n TB ...... ... .. . 
(b) vas te stel of my baba TB het.. 
12. My baba se naam is gesJ..:ryf oJ.> al die blo(::d buisl~s. 
D . Ek het ingestem om my baba in die studie in tc skryf omdat 
o 
o 
o 
u 
o 
(a) my baba dalk beter behandeling mag kry. . 0 
(b) ek graag dokters wil help om meel te leer van TB ... . n 
14. Ek het besluit om my baba in te skryf 
(a) al sal my baba geen ekstra behandeling kry nie . 0 
(b) want ek het geweet ek sal 'n skoonheidspakkie ontvang. [J 
15. Indien my baba ' n kneusplek kry van die bloed toetse. moet ek 
(a) Die pol isie ontbled... . 0 
(b) Met '0 verpleegster by die kliniek praat daarool..... 0 
(c) Na my huisdokter gaan by sy spreekkamers... [J 
16. Ek is In my hUistaal in hierdie studie ingeskryf ......... . o 
17. Ek sal weer aan die studie deelneem as ek die keuse kry . ...... 0 
18 Watter van dIe volgende regte word gewaarborg deur die 
Suid ·Afrikaanse grondwet? 
(a) toegang tot gesondheidsorg.... .... .... .......... . ...... .. .. n 
(b) geheimhouding van privaatinligting . . .... . . .. . 0 
(c) vryheid van liggaamlike skade.... . ..... .. ..... 0 
(d) gratis gesondheidssorg vir almal .. .. ..... .. . ... ....... .. . IJ 
(e) vryheid van keuse............ ......... . ........ .. . .. ... 0 
o 
o 
o 
o 
[] 
lJ 
[1 
Ll 
[J 
u 
U 
IJ 
[I 
o 
o 
o 
" 
o 
o 
nie 
[] 
[] 
[l 
II 
[] 
(1 
lJ 
[l 
o 
o 
o 
f] 
o 
[1 
n 
U 
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Indien teenstrydige antwoorde gegee is en of sekere van die vrae meer navrae uitgelok het, 
skryf asseblief die vraagnommer neer en voeg toepaslike kommentaar in die spasje 
hieronder. Vra ook of daar enige verdere vrae is en noteer die besonderhede. 
Question Answer Correct? Question 
1 B 13b 
2 A I4a 
3 B 14b 
4 C 15a 
I--
5 B I5b 
6 A I5c "-. 
7 C 16 
8 A 17 
9 C 18a 
lOa Yes 18b 
lOb No 18c 
lIa Yes lRd 
lIb No ISe 
12 No 
13a Total 
The length of time it took to complete the questionnaire was 
(d) Under 10 minutes 
(e) Between 10 and 20 minutes 
(f) Longer than 20 minutes 
Answer 
Yes 
Yes 
No 
Yes 
No 
Yes 
The amount of assistance given by study staff to complete the questionnajre was 
(d) Minimal, only clarifications required here and there 
(e) Moderate 
(f) Substantial, the participant required much hel p 
Name of Consenter of Case Control Study 
(Signature of research nurse) (Date) 
(Signature of data capturer) (Date) 
Correct? 
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A!1pt:ndix F Consent Study questionnaire (Xhosa) 
'<;,.1 j:lI nllilloer 
"QUALITY OF CONSENT" ENXULUMENE NALEMIBU~O. [ 
Participant 
mber name 
YbabY~-----' 
._- -
----
Stud 
T-nll 
Parti 
date 
Dale 
inler 
- - - - ----.. ----
ci pant 
of birth I 
--
of 
view 
Participant 
address 
Language 
spoken at 
Ed u(;jlion 
el Eg. lev 
-T~----
home eg A Gil 
for for 
/ St 8 
Gnldc 8 
CZIT-1 .- - -----
Afrikaans / S \;.mdard R 
-'---- -'----
I 
Ubuyibuzwe ukunika imvumelwano Impendul0 elungileyo ~ 
1. Ndicela ukuba ndize eKliniki namhlanje ukuze: 
a. Usana lwam luze kufumana unyango oluqatha 
b. Usana Iwam luthabath~ inxaxheba kuphando 
(; Usana lwam luzakufumana unyango IwesiqheJo 
2. Injongo zoluphando kuku: 
a. Ukujonga ukuba usana lwam lukhuselekile na kwiT.B egazini lalo 
b Ukukhangela ukuba lune T.B na egazini 
c Ukujonga ukuba I inentsholongwane ugawulayo egazini 
Abophando bafuna ukubalisela usana lwam kuphando ukuzt:: 
J. Bavavanye ukuba mana Iwam linayo iT.B okanye ugawulayo na 
b. Ukuze barsale igazl kusana lwam 
c. Ukuze bafake iBeG ngenaliti kusana Iwam 
4. Ixesha alilmdelekileyo eliyakuthi usana lwam luthathe Inxaxheba ngalo 
a. Ylminyaka emibini ukuya kwemithathu 
b. Ziveki azisibhozo ukuya kwezilishumi elinesinc 
c. Lusuku olunye 
-" Eyona ngxaki ibakho xa kutsalwe igazi kusana Iwam yile: 
a. Usana lwam JungasuJeleka kwiT.B okanye kWlDtshoJongwane uG3uJayo 
b. Usana lwam ;ungaba nendawana encinci ebonakalayo apho kutsalwe khona 
igazi nentwana yegazi ephumayo 
c. Usana Iwam lungal1hlekelwa ligazi el ininzi 
b. UmvLlzo endithi ndiwufumane ngenxa yokuthabatha kosana Iwam inxaxheba 
Koluphando yilt>: 
a. Akukho maJungelo angamanye endizakuwafumana 
b. Umntwana wam uyakukhuseleka kwiTB 
c. Umntwana wam uyakufumana unyango olungcono eKliniki 
7. Ukuba andifuni kuthabatha nxaxheba koluphaJldo ndinako ukurhoxa ngalonto: 
a. Mna nosana Iwam asiyikuvumeleka kunyango eziKllnlki 
h. Andiyikulahlekelwa nto, ngamalungelo okanye kunyango kumaziko empilo 
c Akukho nanye into eyakuthi indiphose kumalungelo awo naluphi na uhlobo 
kumaziko empilo 
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s. Iincukacha ngokunxulurnene nosana IW<irn azinakuditvaniswa negazl lakhe 
a. ltnornbolo nezazisi ezifihlakeleyo ziyakusttyenziswa ukugclna igazl 
lingaziwa 
b. Abezophando abaphezulu boyigclna iyimfihlelo yonke Into malunga nosana 
Iwakho 
c Auasebenzi baseKlinlki bakuqmisekisa ukuba banganikezl ngenwkacha 
kubaphandi 
Y. Igazl 10sana Iwarn elifakwe kwisikhtncezisi esiphezulu lagcinwa liyakusetyenziswa 
a Kwarnanye arnazwt' nakwabanye abantwdna bophando 
b. Liyakuvavanyelw:l intsholongwane ugawulayo (HIV) 
(. Ukwenza olunye uxilono ukuthimelii iTB 
C..h.aza ukuba uyavurnelana kusini na Iq.vj:z;ihlok.o ezingazantsi ngokutm l.Ibonakalise 
!!I2hawu kwibokisiJ1J~,anye esecalenl kwesihloko 
Ewe Hayi Andazi 
10. Izinto eztnziwt kus:lna Iwamkoluphando zezi: 
a. Zikhuselekile yaye azinangozi: ........ . 
b. Ziyingozi .............. . 
11. Igazi losana Iwarn liyakubalwalosetyenziswelwa 
a. Ukucedisa uvavanyo kwiTB ... 
b Ukukhangela ukuba usana lwarn lunayo iTB ........ . 
12.lgama losana Iwarn libaliwe ezirnbodleleni ezigalelwe 
[] 
[] 
n 
o 
Igazl .. ... ... ... .. ............ . .. Ll 
13lnjongo zokuza kwarn eKlinikl narnhlanje zezi: 
a. Usana Iwarn lufurnant unyango olungcono.... 0 
b. Ndifuna ukuncedisana noogqira ukuze bazi 
ngapezulu ngesifo seTB. ........... 0 
14. Ndigqlbe ukuba ndilubalist usana Iwam koluphando noxa 
a. Usana Iwarn lungazukufurnana nyango 
lugqithishileyo.... 0 
b. Kuba bendisazi ndizalufumana iharnper 
yezlnto zokutharnbisa... . .......... u 
1). Ukuba usana Iwarn luthe lwane khoko kuJanJawo 
belutsalwe kuyo igazi kumelwe ukuba ndi 
a Ndiyt emapoJ seni .................. .... ... . .. . ... 0 
b. Mdithethe omongikazi eKI iniki. . ... ... ... 0 
c. Ndiye kwagqira endaweni abonela kuyo izigulane.. 0 
16. Ndaxelelwa ngoluphando ngolwirni lwarn ndaza 
ndabaliswa.. ... ... ... .. . . ... [J 
17. Xa bendinokucelwa ukuba ndibalise kwakhona 
bendiya kuthi. ... ... ... ... . . . . ... u 
18. Ngawaphi kulamalungelo alandeLtyo akhuselweyo 
nguMthetho wornZantsi Afrika ngawaphi amalungelo wakho? 
a Ukuya nokufumaneka konyango.... ..0 
b. lrnflhlelo yencukacha zako..... . .. 0 
c. Ukhuseleko ernzimbeni wakho .... u 
d. Uneedo kwezernpilo olungahlawuJelwayo kumntu wonke .. 0 
e Ukuzikhetela ngokukhululekileyo? .................... . .... 0 
n 
[J 
[] 
o 
[j 
[] 
n 
L.J 
o 
0 
0 
0 
0 
0 
o 
o 
o 
[] 
[I 
o 
o 
o 
[] 
[] 
o 
o 
LJ 
n 
[J 
[] 
L".I 
[l 
0 
u 
o 
n 
u 
[l 
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Xa kuthe kwakho ukungangqinelani okanye kwakho ingcaciso ezithe zenziwa nceda 
qaphela inombolo yombuzo uze ubhale ecaleni kombuzo lowo . 
Buza ukuba ingaba ikhona na imibuzo kwaye uyibhale nayo. 
Question Answer Cor rect? Question Answer Correct? 
1 B 13b 
2 A 14a 
3 B 14b 
4 C ]5a 
5 B ISb 
6 A ISc 
7 C 16 
8 A 17 
9 C 18a 
lOa Yes 18b 
lOb No 18c 
lla Yes 18d 
lIb No 18c 
12 No 
13a Total 
The length of time it took to complete the questionnaire was: 
(g) Under 10 minutes 
(h) Between 10 and 20 mi nutes 
(j) Longer than 20 minutes 
Yes 
Yes 
No 
Yes 
No 
Yes 
The amount of assistance given by study staff to complete the questionnaire was : 
(g) Minimal, only clarifications required here and there 
(h) Moderate 
(i) Substantial, the participant required much he! p 
I Name of Consenter 
(Signature of research nurse) (Date) 
(Signature of data capturer) (Date) 
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"QVALITY OF CONSENT" EVALllATION CONSENT FORM 
Sc-n:d nlllnb,-"r 
Dear 
[ 
Thank you for coming to the clinic. wIth your baby today. 
You Just spoke to a nurse about enrolling your baby In a study, and you agreed by signing 
a consent form As part of the ongoIng process of ensuring that good quality inforrnt:d 
consent is given by participants in research studies, the BeG study team wishes to ask you 
to answer a few questions after your baby had been seen by the phlebotomy team 
Would you be willing to do this interview? If so, please listen carefully what the research 
nurse has to say. She will explain to you exactly what she wants you to do. Please be at 
ease and answer the questions as best as you can. If you need help with the questions, you 
can ask the research staff in attendance. If necessary, you can leave your child in the care 
of the research assistant who is available to look after your child during the 20 minutes or 
Su of the interview. 
At the end of the interview, your answers will be discussed with you. 
You will receive RSO in lieu of the time you spent in order for us to collect valuable 
information to improve our quality of research. 
Remember, you can also choose not to stay behind for the quality of consent evaluation 
exercise, and leave immediately after your baby had been seen by the phlebotomy nurse 
I ag;rt:e to assist the BeG research team by participating in the quality of consent survey. 
- -------- - ---_._ - ------_. --- - -----
(Signature of parent I caregiver) (Date) 
I have received R 50 in cash from the research nurse of the BeG study. 
(Signature of parent I caregiver) (Date) 
(Signature of research nurse) (Date) 
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Appendix H: Consent Study Consent form (Afrikaans) 
"QUALITY OF CONSENT" EVALUASIE TOESTEMMINGSBRIEFIE 
SerIal numbe. 
Geagte _ ______ _ ___ _ r----- "J ~----,----
Dankie dat u vandag u baba na die kliniek f,ebflng het. 
Jy het nou net met 'n verpleegster gepraat in verband met die deelname van u baba in 'n 
navorsingsprojek. Jy het aangedui dat jy instem deur op 'n toestemmingsbriefie te te:ken. 
Die BCG studie span wens hiermee om aan u 'n paar te stel nadat u baba ondersoek: is deur 
"Phlebotomy" span om te verseker dat die proses van verkryging van iniigte toestemming 
deurlopend korrek toegepas word. 
Sal jy bereid wet's om met ons 'n klein onuerllOud te hCJU daaroor? Indien weI, vra ons u 
om asseblief noukeurig te luister na die verpleegster. Sy sal verduidelik hoe hierdie 
onderhoud gevoer moet word. Wees asseblief gernaklik en beantwoord die vrae so goed as 
wat jy kan. Indlen JY hulp verlang met enigt van die vrae, vra gerus enige van die studie-
personeel. lodlen nodig kan jy gerus JOu baba by die assistant laat, aangesien die hde 
proses omtrent 20 minute sal neem. 
Aan dip, tinde van die onderhoud sal JOu antwoorue met jou bespreek word. 
Jy ~al ook R50 ontvang vir die tyd wat jy spandeer het am ons te he! p om waarde:volle 
inligting te versamel. 
Onthou, indien jy verkies om nie in hierdie studie deel tt neem nie, mag jy we1er en die 
kliniek verlaat, sonder dat daar enige vrae gevl a sal word 
Hiermee gee ek toestemming om deel te neem aan die BeG navorsing span sc ondersoek 
oor die kwaliteit van die inligtingte toestemming. 
----------- - -
(Handtekening van ouer I voog) (Datum) 
Ek het R50 in kontant ontvang van die navorsingsverpleegkundige 
(Handtekening van ouer I voog) (Datum) 
------ -- -- ---
(Handtekening van novorsingsverpleegkundige) (Datum) 
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A.Q.Q~ndix J Consent Study Consent form (Xh05.cU 
IFOMU YOMGANGATHO OPHEZULU MALUNGA NEMVUMELELWANO 
Mzali Othandekayo _ ___ ___________ _ 
Siyabulela ngokuzisa usana Iwakho ekliniki namhlanje . 
Uthethile nomongikazi malunga nokubaiisa US;ina Iwakho wasayina isivumelano. Nje 
ngenkqubo eqhubekekayo sll1qwenela ukuba isivumelelwana esilungileyo sinikwe 
ngabathathi nxaxheba kuphando.abaphandi be··BCG banqwenela ukubuza imibuzo 
esinqwenela ukuba uyiphendule emva kokuba usana Iwakho luboniwe ngabathathi begazi. 
Uyavuma na ukuphcndula Ie mbuzo? Uba uyavuma mamela ngononophelo lento 
izothethwa ngomongokazi wophando. Uzakukueaeisela yonke into afuna ukuba uyenze. 
Umongikazi oqeqeshelwe oluphando ngokukodwa uzakwenza lemibuzo elula ukuqonda 
ukuba uvumelelwana lubenempumelelo kangakanani. Needa ukhuleke ukuyiphendula 
kangangoko lemibuzo. Ukuba ufuna uneedo malunga nemlbuzo ungabuza abophando 
abakhoyo ngeloxesha lemibuzo. 
Emva koko iimpendulo zakho ziyakuxoxwa nawe. 
Uyakufuma lSlpho esixabisa amashumi amahlanu eRandi (RSO) ukukuxolisa ngexesha 
lakho ukuze sifumani inkeukaeha eyakuthl iSl nike umgangatho ophezulu kuphando Iwetu. 
Ukuba kuyimfuneko, siyakuba nomntu oyakulujonga usana lwakho imizuzu engameshumi 
amabini dixesha ubuzwa 
Khumbula unako ukwala xa ungafum kuyiphendula Itmibuzo uhambe emva kokutsalwa 
kwegazi. 
Ukuba unqwenela ukuthatha inxaxheba kulemvumelwano needa unike imvumelelwano 
ngokuthi utyikitye igama lakho nomhla kwislkhewu esilungele oko. 
Ndiyavuma ukuneeda abophando ngokuthi ndithathe inxaxheba. 
(Utyikityo lomzali lumntu omele umzali) (Umhla) 
Ndifumene amashumi amahlani eRandi (RSO) kumongikazi wophando IweBCG. 
(Utyikityo Iomzali lumntu omele umzali) (Umhla) 
(Utyikityo Ionesi wophando) (Umhla) 
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APPENDIX J. PHLEBOTOMY SCHEDULE FOR PERIOO 01 MARCH to 15 JUL Y 2004 ,
Born she, Born before Bleed D91s _ D~ AnHIL Clinic 1 Clinic 2 Comments 
---
24-Nov-03 5-Jan-D4 I·Mar-04 Monoay Worcester MeJia Pielerse RawsorMloe 
-- --
2:rNov-03 6-Jen-04 2-Mar-04 Tueoday Ceres Wolse/ey ~ -- - -----
2t>-NOI.'{)3 7-Jen-D4 ~Mar-04 We<Jnesday Robertsoo Cogmansl<loof ._ Zolani 
-- 1-- -- - I--
27-Nov-03 8-Jan-04 4-Mar-04 Ttusday Worcester De Dooms Born"",*, 
----
r- - - - - -- --
1-Dec-03 12-Jan-04 8-Mar-04 Monday WOfctster flAaria Pielerse E~iswM 
- - -
2-Dec-03 I~Jan-D4 9-Mar-04 Tuesday Ceres AIlnle BrO'W'n Ned 
:J.-0ec-03 14-Jao-04 10-Mar-04 WedIlesday Robertson _ Victona ~ f--
4-Dec-03 1~J.0-04 11-Mor-04 TIvsday 'Worcester li1~ersdorp Breerivief 
-
8-Dec-03 19-Jan-04 I5-Mar-04 Monday Worcester Mana Pieterse OIeftlex 
-
9-Dee-03 2O-Jan-04 18-Mar-04 Tuesday Ceres Beia PA Hamel 
10-Dec. 03 21-Jan-04 17-Mer..Q4 W O<t1&sday _~Ol>ertson ~ McGregc)f -
ll-Dee-03 22-Jan-04 18-Mor-04 ThlTsdo..r. Worcester 
-
~DoOO1s Touwsriviff 
--
- -
15-Dec-03 2&Joo-04 22-Mar-04 Monday Worces1er HUMAN RIGHTS DAY - PUBLIC HOLIDAY 
--
1t>-Dee-03 27-Jan-D4 23-Mor-04 Tuesday Ceres BaIa \/Ista De Wei Started al De Wet d ntc 
-
f"'- - ------- -
17-Dee-03 28-Jan-04 24-Mar~04 WeQ-lesday Rober1son CogmansJdoof Zoleni 
18-Dec-D3 2g..Jan-04 ~Mar-04 Thucsday _ Worcester \III ersdorp BonnievaJe 
-- -
--
22- Dec-03 2-FeIJ-04 29-Mar-04 Momay Wore.,.. ... Malia Pief,erse RBWSorMie 
, 
2~Dec-OJ 3-FeIJ-04 3D-Mer·04 Tuesday Ceres Amie Br""", NdtJII 
24-Dec-03 4-FeIJ-04 3 1-M. r-04 W_ day RoDer1S00 Stroodak Nkqubela 
-
2:>-Dec-03 5-FeIJ-04 l-AjJr-04 Ttusday W()(cofiter De Dooms San<lllis Cb"lic canceled 
-
-
29-Dec-03 9-Fet>-04 5-AjJr-04 Moodily W orcester Maria Pielerse ~iswerl 
~~ IO-fel>-04 6-Apr-04 ~ay Ceres Bela Vi"" PI< H",rlt<1 
31-Dec-03 1'-Feb-04 7-Apf-04 wednesday RoberlSOfl VlcIUfi~ Asi'txr'i 
1-Jan-D4 12-FeIJ-04 8-AjJr-04 Ttusday Worcester Vllef":dOrp Breerl .... l« 
I-- f- r- -
Wan-D4 16-Feb-04 12-Apr-04 Mooday Worc8ster PUBLIC HOLIDAY IFAMILY DAY I 
6-J&r>-04 17-Feb<J4 1.'1-Apr~~ ~~y Cerc~ NO PHLEBOTOMY CLINIC 
7-Jan-04 18-Fet>-04 14-~-O~ We<r>esday RoI>er1soo PUBLIC HOLIDAY I ELECTIONS I 
8-Jan-04 19-Fe1J-04 ....l~Apr-04 Ttus<Jay Worcester NO PHLEBOTOMY CLINIC 
-
- ---
r- 12-Jan-04 2~Fet>-04 19-Apr-04 - Monday WOfce'Ster Man. Plelers. E'~IIS\',eri 
1~.n-04 24-Fe1J-04 2D-Apr-04 Tuesday COfes WofseIe'l TUI>a\1l 
--2-I-Apr-~4 CognMskloof --14-Jan-Q4 2S-Feb-04 Weal8Sday Robertson Zolani 
15-Jon-04 2t>-FeIJ-04 22-AjJr-04 Tlusday Worcester lAiarsdorp BOme'J8te 
r-
19-Jan-04 l-Mar-04 26-Apr-04 Moo;Iay V\lOfcesler Mari. Pieterse RawsaMle 
2O-Jon-04 2-M.r-04 27-Apr-04 Tuesday C ... es PUBLIC HOLIDAY (FREEDOM DAY) 
----
21-Jao-04 3-Mar-04 28-AjJr-04 Wednesday Rober1son Strooidak Nkq<.Jbela 
- -
22-Jan-04 4-Mor-04 21t-Apr-04 Ttusday Worcester De OQoms Bomevale 
r--- - -
26-Jan-04 8-Mor-04 ~M.y-04 Monday ~cesler Maria Pielerse r----- -- r--- -
---
~--. 
--
27-Jan-Q4 9-Mar-04 4-May..04 Tuesday Ceres Bela Vista PA Hamlet 
28-Jan-D4 10-Mar-04 5-May-04 W~sday Rober1son Victoria ~ 
---
29-Jan-04 11-M8{-04 t>-May-O.! r!-l'usday Worcester V1lersdorp Breerivie( 
----
2-Fet>-04 ~~ f- 1 ()'May-04 ~-- Wofcester !Aarie Pie1erse CM!rt1ex 
~Fet>-04 16-Mor-04 11-May-04 Tuesday Ceres ~y TultJagh 
r-
4-Feb-04 17· Mor-04 12·May-04 Wectlesday Robertson Strcoidak McGregor 
Ii-FeIHl4 13-Mor-04 1~May-04 Thusday W orces1er De Dooms Sandllls 
9-Fet>-04 22-M8r-04 l7-May-04 Monday Worcester Maria Pieterse Empol""""; 
-
- ----
10-FeIJ-04 23-Mar-04 l8-May-04 Tuesday Ceres B618 ViS1a De Wei 
-
11·Feb-04 24-Mar-04 1!J-May-04 W _ ay RotMof1soo C<J9!l1ans~~ Zolarl 
12-Fet>-04 25-M8r-04 2O-May-04 Thursday W orcester Vlliersdap BoMiwdle 
- -----
- I--
16-FeIJ-04 29-Maf-04 24-May-04 Monday Woccester Maria PJelerse RdwsorM" 
----
17-Fet>-()4 30-Mar-04 2trMay~ 
-
Tuesday Ceres Amle Brown Nruli 
l8-feb-D4 31-Mar-04 26-M~04 W_day Robe(1son StrOQklak NK~ ~~ 
19-FeI>-04 l -AjJr-04 27-May-04 Thufs<ll>y Worces'- ~Dooms San<lllis 
'- '--
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
.-- - -
23-Fet>-04 5--Apr-04 31-May-D4 !!..OI1day ___ ~cester Maria Pieterse ErrpI'-' 
-
~ 
~24-F~~ _ 6-Apr-D4 l-Jtn-04 Tuesday Ce<es _ Vista PA Hamlet 
- ---
25--FeI>-04 7-Apr-04 2-Jm-04 Wednesday Rober1son Victoria AS~ ___ 
---
26-FetHl4 6-Apr-04 3-Jun-04 Ttusday WOfCf!s1ef V,' ersClorp SreeriviBf 
-- --
- -
-
-, 
1-Mar-04 12-Apr-04 7-Jun-04 Monday Worces ter Maria Prelerse 
-- -- -
2-Mar~ 13-Apr-04 6-Jtn-04 ~ COf'e<. Wolseley TLl>agh 
3-Mar-04 14-Apr-04 9-Jtn-04 Wemesday Robertson StrOOOClek McGregor 
- -
r--4-~ 
- -
15--Ajl<-04 10-Je<>-04 Too-sday Worcest€( De Dooms SAn<hts 
--
-- ------
6-Mar-04 19-Apr-04 14-Jur>-04 Monday \NorceSler Mana ""~terse fnl)II~i'",Gn 
9-Mar-D4 2O-Apr-D4 15-Jtn-04 Tuesday 
,-~'--- Bela VI"'> De W e' 
10-1oCar-D4 21-Apr-D4 16-J~04 Wemesday Rob«'tson PUBLIC HOLIDAY ,YOUTH DAY) 
.--!_I-M~~ 
- -
22-Apr-04 17-Jun-04 Thursday \'lJorcester ViWers<lO<p Bvnnle'/ate 
.-
-
15-Mar-D4 26-Apr-D4 21 -Jun-04 M<l{\(jay Worcester M~uia Pieterse RSWSOf1V11e 
16-M"r-<l4 27-Apr-o-l 22-J1n-04 TueWov Ceres Arv\ie 8foo.Hn NWI! 
17-M.r-D4 2S-Apr.()4 2:>-Joo-04 Wednesday Robertsoo Strooidolk N~ 
1S-Mar-D4 2S-Apr.()4 24-Jtn-04 Thl.<Sday WO(cester De Dooms 
_IS 
f--- -
e- 22·Mar-04 3-May-D4 2S-JL<>-Q4 Monday 
Worcester Marla Ple'er$e EfT!lllswffiI 
23-1.4ar-04 4-M8y-04 29-J<n-04 Tuesday Ceres Be~a Vi sla PA H1!U-,-.et 
--- -- -
24-Mar-04 5--May-04 3O-Jtn-04 Wemesday Rob.;r1ooo \I1c loria As~ 
-
25-Mar-D4 6-May-04 l -JU-04 Tlu sday W orCrJSltrr 'AI ",y:\o(p Br&M'.oIfer 
29-Mar-04 10-May-D4 5-JLl-04 Mooday Worce s.ter Msria pjelerse <Ml<hex 
- -- --
-- -
3()'Mar-D4 l1-May-04 
-
6-~ T(~~y' Cere<. W ol5eIfIy T<ibagh 
- ---
31-Mar-O" 12-May-04 7-J tA-04 'Wemesdoy Rob.;r1SO<l Strooldak McGregor 
l-Apr-D4 13-Moy-04 S-Jut-04 Th.Jrsd6y I/IlorC&st.er De Dooms Sand1lls 
-
5--Apr-D4 17-May-04 12--JLI-04 Monday Warc&S!Of Mana Plelerse ~"""''''; I 
~Apr-D4 lS-May~ 13-JtJ-04 Tuesday Ceres Bel. Vista De Wet 
-
I--- 7-Apr-04 19-Ma}'::D4 14-JtJ-04 Wednesday Rotenson Coga>~loor ZOiafll 
S-Apr-O~ r- 20- MaX-04 1!;-J1JI..04 Ttvsdwj ~'Vorcester 1f,Iersdarp BomIevaJe 
